Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XSTEM-OA in Symptomatic Knee Osteoarthritis
NCT05344157Phase 2Completed
- Sponsor
- Xin Du Bio-Tech
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XSTEM-OA in osteoarthritis (OA), sponsored by Xin Du Bio-Tech. Primary endpoints: Adverse Events (AEs) at 24 months, 12-lead electrocardiogram (ECG) at 18 months and 3 more. Started Jun 2022; status: completed.
02
Drugs
XSTEM-OA
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05344157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344157.